Compass Pathways Completes FDA Drug Application for Psilocybin Depression Treatment
Nov 9 (Reuters) - Compass Pathways PLC CMPS.O:
COMPASS PATHWAYS COMPLETES COMP360 PSILOCYBIN NEW DRUG APPLICATION TO U.S. FDA FOR TREATMENT-RESISTANT DEPRESSION
COMPASS PATHWAYS - EXPECTED LAUNCH OF COMP360 IN H1 2027 SUBJECT TO FDA APPROVAL
Further company coverage: CMPS.O